Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The intestine is one of the first affected organs in Parkinson's disease (PD). PD subjects show abnormal staining for Escherichia coli and α-synuclein in the colon. METHODS: We recruited 52 PD patients and 36 healthy cohabitants. We measured serum markers and quantified the numbers of 19 fecal bacterial groups/genera/species by quantitative RT-PCR of 16S or 23S rRNA. Although the six most predominant bacterial groups/genera/species covered on average 71.3% of total intestinal bacteria, our analysis was not comprehensive compared to metagenome analysis or 16S rRNA amplicon sequencing. RESULTS: In PD, the number of Lactobacillus was higher, while the sum of analyzed bacteria, Clostridium coccoides group, and Bacteroides fragilis group were lower than controls. Additionally, the sum of putative hydrogen-producing bacteria was lower in PD. A linear regression model to predict disease durations demonstrated that C. coccoides group and Lactobacillus gasseri subgroup had the largest negative and positive coefficients, respectively. As a linear regression model to predict stool frequencies showed that these bacteria were not associated with constipation, changes in these bacteria were unlikely to represent worsening of constipation in the course of progression of PD. In PD, the serum lipopolysaccharide (LPS)-binding protein levels were lower than controls, while the levels of serum diamine oxidase, a marker for intestinal mucosal integrity, remained unchanged in PD. CONCLUSIONS: The permeability to LPS is likely to be increased without compromising the integrity of intestinal mucosa in PD. The increased intestinal permeability in PD may make the patients susceptible to intestinal dysbiosis. Conversely, intestinal dysbiosis may lead to the increased intestinal permeability. One or both of the two mechanisms may be operational in development and progression of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with most of the diseases, PD patients have a different microbiota composition compared to healthy controls or patients affected by other neurological disorders (174–176).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [174]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A clinical study revealed that the level of serum LPS-binding protein in patients with Parkinson's disease was lower than that in controls, indicating that increased intestinal permeability and increased invasion of Gram-negative bacteria leads to an increase in LPS in the circulatory system.148”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“serum from PD patients contains low levels of LPS binding protein [145,146], which are indicative of a chronic systemic exposure to LPS and gram negative endobacteria [147,148,149]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [145]
In the citing paper
“Reduced number of Prevotella may be associated with decreased mucin synthesis causing increased gut permeability [413].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Postmortem studies of non-PD subjects disclosed incidental α-synuclein-positive Lewy bodies in the gastrointestinal tract, the olfactory system, and the cardiac sympathetic system, which suggests that α-synuclein pathology in PD may start in these tissues [2].”
BackgroundDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
(2023) · doi:10.1126/science · Cited by 6,063
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 2×
“Direct evidence supporting the notion that intestinal microbiota determines a clinical phenotype has been recently reported in obesity [9].”
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472 · cited 1×
“PD is predicted to affect more than 10 million people worldwide by the year 2030 [1].”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 3×
“In contrast to Prevotella, the count of Lactobacillus was increased 22-fold in the previous report [10], and 6.”
BackgroundResultOccurrence, Classification, and Biological Function of Hydrogenases: An Overview
Vignais, P. M., & Billoud, B. (2007) · Chemical Reviews · doi:10.1021/cr050196r · Cited by 1,578 · cited 1×
“According to an extensive review of bacterial hydrogenases [25], B.”
BackgroundDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 1×
“Intestinal microbiota in PD was recently published [10, 11].”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · cited 4×
“In PD, intestinal permeability is increased and the hyperpermeability is correlated with increased intestinal staining for Escherichia coli; nitrotyrosine, a marker for protein oxidation; and α-synuclein [7].”
BackgroundResultInfluential
Cited by
Items 301–400 of 538
Roy, R., Kumar, D., Bhattacharya, P., & Borah, A. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105803 · Cited by 20
Korsten, S. G. P. J., Hartog, M., Berends, A. J., Koenders, M. I., Popa, C. D., Vromans, H., Garssen, J., van den Ende, C. H. M., Vermeiden, J. P. W., & Willemsen, L. E. M. (2024) · Nutrients · doi:10.3390/nu16193384 · Cited by 19
“The same accounts for LBP [47–49].”
High levels of Bifidobacteriaceae are associated with the pathogenesis of Parkinson’s disease
Zuo, S., Wang, H., Zhao, Q., Tang, J., Wang, M., Zhang, Y., Sang, M., Tian, J., & Wang, P. (2023) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2022.1054627 · Cited by 19
“Similarly, accumulation of alpha-synuclein (α-syn) in the enteric nervous system (ENS) may begin 20 years before the onset of degenerative changes in the central nervous system (CNS) and motor symptoms associated with PD (Hasegawa et al., 2015).”
BackgroundSantos-Rebouças, C. B., Cotrin, J. C., & dos Santos, G. C. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111875 · Cited by 16
Microbes in Health and Disease: Human Gut Microbiota
Hu, C., & Shen, H. (2024) · Applied Sciences · doi:10.3390/app142311354 · Cited by 19
Parkinson Disease and the Gut: A Primer for Gastroenterologists
Sharma, A., Voigt, R. M., Goetz, C. G., & Keshavarzian, A. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003508 · Cited by 19
Das Darmmikrobiom bei der Parkinson-Krankheit
Bedarf, J. R., Hildebrand, F., Goeser, F., Bork, P., & Wüllner, U. (2018) · Der Nervenarzt · doi:10.1007/s00115-018-0601-6 · Cited by 27
Nurrahma, B. A., Yeh, T., Hsieh, R., Tsao, S., Chen, C.-W., Lee, Y.-P., Pan, C., & Huang, H. (2022) · Antioxidants · doi:10.3390/antiox11122396 · Cited by 16
“In most clinical studies, the abundance of Prevotella is reported to be lower in PD compared to healthy controls.”
BackgroundInfluentialYao, L., Yang, Y., Yang, X., & Rezaei, M. J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04151-2 · Cited by 16
Mehboodi, M., Namdari, M. P., Abdollahi, Z., Mobarezi, Z., Kiani, M., Chamani, F., Khanbabaie, H., Rabiei, S., Maleki, M. H., Sanati, H., et al. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107905 · Cited by 17
The role of the gut microbiota in the pathophysiology of mental and neurological disorders
Pusceddu, M. M., & Bas-Prior, J. M. D. (2020) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000255 · Cited by 15
“Parkinson Observational study (Hasegawa et al., 2015) 52 PD patients (21♂, 31♀); 36 spouses of patients with PD (21♂, 15♀) PD patients showed ↑lactobacillus levels; ↓Clostridium coccoides group, Clostridium leptum subgroup and Bacteroides fragilis; ↓hydrogen-producing fecal bacteria Observational study (Scheperjans et…”
BackgroundInfluentialGut Microbes and Neuropathology: Is There a Causal Nexus?
Dinan, K., & Dinan, T. G. (2022) · Pathogens · doi:10.3390/pathogens11070796 · Cited by 17
“Clostridium coccoides, Bacteroides fragilis ↓ [37]”
The Importance of the Microbiota in Shaping Women’s Health—The Current State of Knowledge
Krupa-Kotara, K. H., Helisz, P., Gwioździk, W., & Grajek, M. K. (2022) · Applied Microbiology · doi:10.3390/applmicrobiol3010002 · Cited by 17
Gut Dysbiosis: A Target for Protective Interventions against Parkinson’s Disease
Lima, I. S., Pêgo, A. C., Martins, A. C., Prada, A. R., Barros, J. T., Martins, G., & Gozzelino, R. (2023) · Microorganisms · doi:10.3390/microorganisms11040880 · Cited by 15
Regulation of Pain Perception by Microbiota in Parkinson Disease
Manjarres, Z., Calvo, M., & Pacheco, R. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000674 · Cited by 15
Huang, C., Zhang, W., Shen, Z. J., Li, M., Yin, J., Tang, Y., Zhou, X., Zhu, X., & Sun, Z. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148757 · Cited by 14
Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson’s Disease?
Koukoulis, T. F., Beauchamp, L. C., Kaparakis‐Liaskos, M., McQuade, R. M., Purnianto, A., Finkelstein, D. I., Barnham, K. J., & Vella, L. J. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230315 · Cited by 16
“Since 2015, our understanding of the microbiota-gut-brain axis has evolved after several groups found that PwP exhibit an altered gut-microbiota compared to healthy controls [91–93].”
BackgroundOral and gut microbiome profiles in people with early idiopathic Parkinson’s disease
Stagaman, K., Kmiecik, M. J., Wetzel, M., Aslibekyan, S. W., Sönmez, T. F., Fontanillas, P., Auton, A., Babalola, E., Bell, R. K., Bielenberg, J., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00630-8 · Cited by 19
Yıldız, G. B., Kayacan, Z. Ç., Karacan, İ., Sümbül, B., Elibol, B., Gelişin, Ö., & Akgül, Ö. (2023) · Acta Neurologica Belgica · doi:10.1007/s13760-023-02195-0 · Cited by 17
“There are many studies showing that the duration of the disease causes changes in the gut microbiota in PD [8, 29].”
BackgroundPeter, I., & Strober, W. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230021 · Cited by 15
“fragilis and Bifidobacterium has been associated with worsening of motivation/initiative and hallucinations/delusions, respectively, using the Movement Disorder Society-United Parkinson’s Disease Rating Scale (MDS-UPDRS) scoring system [86], while the Clostridium coccoides and Lactobacillus gasseri species have report…”
MethodThe Human Microbiome—A Physiologic Perspective
Yang, X. J., Louwies, T., Mars, R. A. T., & Kashyap, P. (2024) · Comprehensive physiology · doi:10.1002/cphy.c230013 · Cited by 15
Is Gut Dysbiosis an Epicenter of Parkinson’s Disease?
Rajput, C., Sarkar, A., Sachan, N., Rawat, N., & Singh, M. P. (2021) · Neurochemical Research · doi:10.1007/s11064-020-03187-9 · Cited by 14
Radulescu, C. I., Garcia‐Miralles, M., Sidik, H., Bardile, C. F., Yusof, N. A. B. M., Lee, H. U., Ho, E. X. P., Chu, C. W., Layton, E., Low, D., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104744 · Cited by 14
“, 2015), and was associated with increased gut permeability (Hasegawa et al., 2015).”
BackgroundBoschetti, E., Neri, I., Follo, M. Y., GIORGIO, R. D., Cocco, L., Manzoli, L., & Ratti, S. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220622111501 · Cited by 15
Gil-Martínez, A. L., Estrada, C. M., Cuenca‐Bermejo, L., Cano, J. A., Valiente, M., Martínez, C. M., Fernández‐Villalba, E., & Herrero, M. T. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-0010-z · Cited by 15
Neuroimmunogastroenterology: At the Interface of Neuroimmunology and Gastroenterology
Sanchez, J. M. S., McNally, J. S., Cortez, M. M., Hemp, J., Pace, L., & Clardy, S. L. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00787 · Cited by 15
Influence of aerobic exercise training on mice gut microbiota in Parkinson's disease
FAN, T., LI, X., ZHANG, X., ZHANG, J., SUN, L., CHEN, J., & FU, C. (2022) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2617 · Cited by 13
“Increased Lactobacillaceae are related with a severe clinical profile, including higher frequencies of cognitive impairment and PD subtype (Barichella et al., 2019) and high levels of Lactobacillus is related with advanced PD (Hasegawa et al., 2015).”
BackgroundAmyloids and Amyloid-like Protein Aggregates in Foods: Challenges and New Perspectives
Malik, S., & Yadav, J. K. (2023) · Current Protein and Peptide Science · doi:10.2174/1389203724666230104163924 · Cited by 12
The gut-brain axis in the pathogenesis of Parkinson’s disease
Meng, L., Yuan, X., Cao, X., & Zhang, Z. (2019) · Brain Science Advances · doi:10.1177/2096595820902566 · Cited by 13
“Clinical investigations have demonstrated that the microbiomes of PD patients were significantly different from those of control subjects [26, 36, 37].”
BackgroundClostridioides difficile and neurological disorders: new perspectives
Biazzo, M., Allegra, M., & Deidda, G. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.946601 · Cited by 11
“Also, gut microbiome dysfunctions are common (Hamano et al., 1993; Clairembault et al., 2015; Hasegawa et al., 2015; Keshavarzian et al., 2015; Klingelhoefer and Reichmann, 2015; Mulak and Bonaz, 2015; Unger et al., 2016; Bedarf et al., 2017; Hill-Burns et al., 2017; Parashar and Udayabanu, 2017; Scheperjans et al., 2…”
BackgroundKrothapalli, M., Buddendorff, L., Yadav, H., Schilaty, N. D., & Jain, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126678 · Cited by 13
Ageing, proteostasis, and the gut: Insights into neurological health and disease
Akbar, M., Toppo, P., & Nazir, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102504 · Cited by 15
The role of the gut microbiota in neuropsychiatric disorders and therapy
Zhang, F., Ding, K., Zhang, L., Liu, D., Dong, X., Wang, M., Zhou, F.-L., Sun, Y., Zhang, W., Yu, Y., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102894 · Cited by 12
Moreno, L. O., Bagüés, A., Martínez, V., & Abalo, R. (2023) · Nutrients · doi:10.3390/nu15122775 · Cited by 11
Christensen, L. F. B., Alijanvand, S. H., Burdukiewicz, M., Herbst, F., Kjeldal, H., Dueholm, M. S., & Otzen, D. E. (2021) · Protein Science · doi:10.1002/pro.4137 · Cited by 11
Gut microbiota in Parkinson’s disease patients: hospital-based study
Khedr, E. M., Ali, A. M., Daef, E., Hassan, H. M., Alaa, A., & Gamea, A. (2021) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-021-00407-z · Cited by 13
“However, Hasegawa and colleagues [37] found that non-tremulous PD patients had a higher level of Bacteroides than in tremor subtypes.”
BackgroundFang, X. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0239-x · Cited by 11
Mori, P., Chauhan, M., Modasiya, I. J., & Kumar, V. (2023) · Springer eBooks · doi:10.1007/978-981-99-1463-0_16 · Cited by 12
The ketogenic diet in Parkinson’s disease: a potential therapeutic strategy
Pokora, B., Pokora, K., Binienda, A., & Fichna, J. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00799-2 · Cited by 9
“This, in turn, leads to the formation of what is known as a “leaky gut” [110 , 140].”
The role of the microbiota-gut-brain axis in schizophrenia: an immunological perspective
Su, B.-W., Li, Y., Yang, L.-Y., Yang, H., Wang, W., Ren, H., Bao, Y.-N., Lao, J.-Y., & Luan, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711756 · Cited by 12
Wang, J., Zhang, Y., Wu, Q., Zhong, Y., Xu, Z., & Yang, J. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1757551 · Cited by 21
“LCA is highly hydrophobic and relatively insoluble with a significant portion excreted into feces, while some is absorbed and sulfated in the liver for renal excretion (Stiehl et al., 1980).”
InfluentialPrenatal Isoflurane Exposure Induces Developmental Neurotoxicity in Rats: the Role of Gut Microbiota
Wang, L., Yang, X., Zhou, D., Cheng, T., Zhang, X., & Wu, H. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00487-6 · Cited by 10
“Various strains of Lactobacillus have been found increased in persons with Parkinson’s disease (PD) (Hasegawa et al. 2015; Hill-Burns et al. 2017; Petrov et al. 2017).”
BackgroundGan, L., Wang, Y., Huang, S., Zheng, L., Feng, Q., Liu, H., Liu, P., Zhang, K., Chen, T., & Fang, N. (2024) · Nutrients · doi:10.3390/nu16030342 · Cited by 11
“There are also studies that have reported serious infections due to Lactobacillus , such as bacteremia and liver abscess [63,64], and an increase in Lactobacillus has also been observed in patients with diseases such as type 2 diabetes and Parkinson’s disease [65,66].”
BackgroundThe Microbiome in Neurodegenerative Disease
Brown, E. G., Tanner, C. M., & Goldman, S. M. (2018) · Current Geriatrics Reports · doi:10.1007/s13670-018-0240-6 · Cited by 12
Sharma, P., & Agrawal, A. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01516-2 · Cited by 11
Analysis methods for the gut microbiome in neuropsychiatric and neurodegenerative disorders
Song, J. G., Yu, M., Lee, B., Lee, J., Hwang, S.-H., Na, D., & Kim, H. W. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.02.024 · Cited by 10
“1106 compared with that of healthy controls [71,74,77,80].”
BackgroundPrebiotics and probiotics and Parkinson's disease
Amani, R., & Mehrabani, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90052-2.00034-2 · Cited by 9
Yan, Z., & Zhao, G. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240244 · Cited by 11
“8 Scheperjans et al. reported that the abundance of Prevotellaceae in feces of PD patients was reduced by 77.6% as compared with controls.”
InfluentialMicrobiome and Diseases: Neurological Disorders
Slingerland, A. E., & Stein‐Thoeringer, C. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-90545-7_18 · Cited by 9
Dopamine and Gastrointestinal Motility
Zheng, L., Liu, S., Zhou, L., Zhang, X., Xiao, Y., & Zhu, J. (2021) · Springer eBooks · doi:10.1007/978-981-33-6586-5_5 · Cited by 13
Cheng, Y.-K., & Chiang, H.-S. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08114-w · Cited by 8
Cornò, M. D., Aureli, A., Varano, B., & Conti, L. (2026) · Biomolecules · doi:10.3390/biom16020226 · Cited by 8
“Conversely, comparable or lower endotoxin concentrations were reported in other studies [125].”
Wu, L., Chu, L., Cao, H., Tian, Q., Gao, H., Huo, J., & Gao, Q. (2023) · Food Bioscience · doi:10.1016/j.fbio.2023.103548 · Cited by 9
Alterations in children’s sub-dominant gut microbiota by HIV infection and anti-retroviral therapy
Nguyen, Q. T., Ishizaki, A., Bi, X., Matsuda, K., Nguyen, L. V., Pham, H. V., Phan, C. T. T., Phung, T. T. B., Ngo, T. T. T., Nguyen, A. V., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258226 · Cited by 8
Disease mechanisms as subtypes: Microbiome
Bonvegna, S., & Cilia, R. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00006-0 · Cited by 8
Souza, V. D. S., Manhães‐de‐Castro, R., Pereira, S. D. C., de Silveira, B. S., Calado, C. M. S. D. S., Gouveia, H. J. C. B., Coq, J., & Toscano, A. E. (2025) · Cells · doi:10.3390/cells14141063 · Cited by 7
“More-over, the reduction in Prevotellaceae and increase in Lactobacilliaceae are related to neuroinflammation and were discovered in neurodegenerative diseases such as Parkinson’s disease [71,72].”
Tian, C., Yang, M., Chen, K., Luo, D., Yue, N.-N., Zhao, H., Zhang, Y., Lu, J., Liang, Y.-J., Song, Y., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s514838 · Cited by 9
Alterations of Gut Microbiota and Microbial Metabolites in Parkinson’s Disease: A Systematic Review
Davoody, S., Vakili, K. G., Jazi, K., Fathi, M., Heidari‐Foroozan, M., Mofidi, S. A., Taremi, M., Taherkhani, A., Azadnajafabad, S., Hojjatipour, F., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05598-7 · Cited by 8
“On the other hand, the increased permeability of the gut is possibly due to the reduction in mucin-producing ( Prevotella ) and mucin-degrading bacteria ( Verrucomicro-bia ) in PD patients, which can make them susceptible to microbiome alterations [30, 45].”
InfluentialGut microbiota and parkinson's disease
Huarcaya, L. R. D., Mohammadi, M. R., & Ríos, M. F. D. (2021) · Cellular Molecular and Biomedical Reports · doi:10.55705/cmbr.2021.410426.1165 · Cited by 7
“There was no significant difference in lactobacillaceae between people with Parkinson's disease who did not take a COMT inhibitor and healthy participants [60].”
BackgroundInfluentialZeng, T., Lin, C., Deng, Y., & Zhu, W. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1371791 · Cited by 10
Kacena, C. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuae221 · Cited by 7
Ichikawa, Y., Sato, B., Hirano, S., Takefuji, Y., & Satoh, F. (2023) · Medical Gas Research · doi:10.4103/2045-9912.385949 · Cited by 7
Romo, E. Z., Hong, B. V., Agus, J., Jin, Y., Kang, J. W., & Zivkovic, A. M. (2024) · Nutrition Research · doi:10.1016/j.nutres.2024.11.013 · Cited by 8
Ilie, O., Văcărean-Trandafir, I.-C., Amărandi, R.-M., Nita, I.-B., Dobrin, R., Doroftei, M., Ivanov, I.-C., Săvuţă, G., Kirov, B., & Doroftei, B. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1654995 · Cited by 7
“…treatment (Unger et al., 2016; Hill-Burns et al., 2017; Weis et al., 2019; Hughes et al., 2020; Wallen et al., 2020; Lubomski et al., 2022a), sex-specific microbiome differences (Gao et al., 2018), and geographic diversity in microbial composition (Hasegawa et al., 2015; Keshavarzian et al., 2015).”
The Brain‐Gut Axis in Parkinson's Disease Pathology
Ozkaya, K. S., & Browning, K. N. (2026) · Comprehensive physiology · doi:10.1002/cph4.70137 · Cited by 6
“…compositions and microbial metabolites in PD patients (Nishiwaki et al. 2020), including reduced levels of short-chain fatty acids (SCFAs) and changes in immune signaling, even in early or treatment naïve stages of the disease (Bedarf et al. 2017; Unger et al. 2016; Hasegawa et al. 2015).”
Gibo, N., Hamaguchi, T., Miki, Y., Yamamura, T., Nakaguro, M., Ito, M., Nakamuara, M., Kawashima, H., Hirayama, M., Hirooka, Y., et al. (2022) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4313 · Cited by 6
Self-citationMinamisawa, M., Suzumura, T., Bose, S. K., Taniai, T., Kawai, G., Suzuki, K., Yamaguchi, A., & Yamanaka, S. (2021) · Medical Sciences · doi:10.3390/medsci9010017 · Cited by 6
Dong, X., Yang, T., & Jin, Z. (2025) · Communications Biology · doi:10.1038/s42003-025-09067-8 · Cited by 5
“Other commensal microbes with anti-in fl ammatory effects, including Blautia , Coprococcus , Faecalibacterium , Prevotella , Clostridium coccoides , Bacter-oides fragilis and Roseburia , were depleted in PD patients 10,11 .”
Chi, F., Chen, K., Yin, Y., Hakovirta, J. R., & Saris, P. E. J. (2026) · Sustainable Microbiology · doi:10.1093/sumbio/qvag002 · Cited by 7
“Conversely, reductions in Prevotellaceae , Lachnospiraceae , and Faecalibacterium—taxa often associated with anti-inflammatory and mucosal-protective functions—suggest a potential loss of beneficial microbial activity in PD.”
InfluentialTreating autism spectrum disorder by intervening with gut microbiota
Tu, T., & Zhao, C. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001469 · Cited by 7
The Role of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Parkinson's Disease
Justich, M. B., Rojas, O. L., & Fasano, A. A. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771468 · Cited by 5
Rout, S., Dash, R. J., Satish, V., Venugopal, G., Rao, B. N., Bandhyopadhyay, D., Bhoi, S. K., & Ramadass, B. (2025) · Aging · doi:10.18632/aging.206200 · Cited by 7
da Silva, V. G., Roy, N. C., Smith, N. W., Wall, C. R., Mullaney, J. A., & McNabb, W. C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1591341 · Cited by 7
Sales, P. C. S. L., Neto, A. V. D. S., Costa, L. A., da Fonseca, M. D. M. V., Mendonça, G. D. S., de Araujo, L. V., Araújo, V. S. C., Cardoso, A. M. S., Jordão, P. V. D. S., Araujo, B. D., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i2.12788 · Cited by 5
Rethinking Parkinson Disease: Exploring Gut-Brain Interactions and the Potential Role of Exercise
Zapanta, K., Schroeder, E. T., & Fisher, B. E. (2022) · Physical Therapy · doi:10.1093/ptj/pzac022 · Cited by 5
Tsuji, H., & Nomoto, K. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000479917 · Cited by 6
Self-citationThe many genomes of Parkinson's disease
Payami, H. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.07.007 · Cited by 5
The Double‐Edged Sword: The Complex Function of Enteric Glial Cells in Neurodegenerative Diseases
Mendonça, I. P., & Peixoto, C. A. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70069 · Cited by 5
“Other studies have detected changes in the microbiota of patients with PD, such as low levels of Prevotella, Faecalibacterium prausnitzii , and Clostridial cluster IV (Unger et al. 2016; Hasegawa et al. 2015; Scheperjans et al. 2015; Keshavarzian et al. 2015).”
Roy, S., Chattopadhyay, D., Choudhury, L., Ghosh, S., & Mahajan, A. A. (2025) · Discover Neuroscience · doi:10.1186/s13064-025-00221-w · Cited by 6
Lactobacillaceae and Parkinson's disease: An apparent paradox
van der Maden, M. M., Verbeek, M. M., & Beckers, M. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241312401 · Cited by 9
“36 Catechol-O -methyltransferases (COMT) are enzymes capable of metabolizing levodopa by transmethylation to 3-”
Interplay of alpha-synuclein pathology and gut microbiome in Parkinson’s disease
Srivastava, A., Kataria, A., Yadav, D. K., Han, I., & Choi, E. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91313-3.00003-9 · Cited by 4
Mirab, F., Pirhaghi, M., Otzen, D. E., & Saboury, A. A. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167862 · Cited by 5
Gut Microbiota and Aging: Targets and Anti-aging Interventions
Singh, B., Catanzaro, R., Mal, G., Gautam, S., Mohania, He, F., Yadav, H., Bissi, L., & Marotta, F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62181-5 · Cited by 4
Lami, K. F., de Oliveira, V. F., & Batista, K. Z. S. (2021) · Research Society and Development · doi:10.33448/rsd-v10i4.14185 · Cited by 5
“Hasegawa et al. (2015) also point out that Parkinson's patients have dysbiosis and decreased circulating levels of protein binding to the bacterial LPS.”
BackgroundGiachino, C., Tirolo, C., Caniglia, S., Serapide, M. F., L’Episcopo, F., Bertoli, F., Giuliano, C., Mearelli, M., Jakobi, M., Schneiderhan‐Marra, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.01.505977 · Cited by 5
Karsten, L., Harvey, B. H., Stein, D. J., Valderrama, B., Bastiaanssen, T. F. S., Clarke, G. A., Cryan, J. F., van der Sluis, R., Jaspan, H. B., Happel, A., et al. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.16 · Cited by 3
“Increased plasma LPS concentrations (Fujigaki et al ., 2001), which are associated with systemic infection, gut microbiota composition alterations, and increased gut permeability (Hasegawa et al ., 2015), are therefore an important driver of bolstered IDO activity.”
Gut microbiome species Levilactobacillus brevis regulates reproductive fitness in C. elegans
Braun, N. J., & Mor, D. E. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100471 · Cited by 4
“One such species, Levilactobacillus brevis ( L. brevis ), has been found to be elevated in the gut microbiome of Parkinson ’ s disease patients (Hasegawa et al., 2015).”
Human Microbiota-Associated Pig Models for Translational Microbiome Research: A Scoping Review
Wang, S.-J., Nian, H., Chen, Z., & Cui, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041987 · Cited by 3
“A growing body of research has examined the human microbiome’s influence on neurological disorders [145–147], where gut microbiome dysbiosis is commonly reported [148–150].”
Mendonça, I. P., da Silva, R. S., de Paiva, I. H. R., Costa, B. L. D. S. A., Teixeira, K. P. D. S. B., de Souza, J. R. B., & Peixoto, C. A. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02152-2 · Cited by 6
“…(Karlsson et al. 2013 ), asthma (Abrahamsson et al. 2014 ), and in neuropsychiatric and neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, autism, and depression (Fond et al. 2015 ; Hasegawa et al. 2015 ; Quigley 2017; Hirayama and Ohno 2021 ).”
Losanto, J., Langjahr, P., Barrios, G. M., Paats, A., Acosta, M. E., Guillén, Y., Duarte, M., Acosta-Colman, I., & Cervera, R. (2021) · Lupus · doi:10.1177/09612033211050321 · Cited by 4
Ketter-Katz, H., Saeed, R., Sher, I., Altmann, G., Shadi, T., Dallasheh, S., Lustig-Barzelay, Y., Sabo, A., Jejelava, G., Hadar, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-70960-z · Cited by 4
“While Clostridia Clostridiales taxa were shown to be increased in Neuromyelitis Optica (NMO) patients 58 , they were shown to decrease in Parkinson’s disease (PD) patients 57,59 .”
BackgroundA Novel Rat Model for Inflammatory Gut–Brain Interactions in Parkinson's Disease
Kendall, G. E., Underwood, C. F., & Parr‐Brownlie, L. C. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.16667 · Cited by 4
Intestinal dysbiosis leads to the reduction in neurochemical production in Parkinson’s disease (PD)
Kumar, R., & Kumar, R. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.004 · Cited by 3
Fecal Microbiota Transplants as a Treatment Option for Parkinson’s Disease
Flameling, I. A., & Rijkers, G. T. (2018) · IntechOpen eBooks · doi:10.5772/intechopen.78666 · Cited by 3
Die Rolle des Darmmikrobioms beim idiopathischen Parkinson-Syndrom
Unger, M. M., Becker, A., Keller, A., Schäfer, K., Schwiertz, A., & Oertel, W. H. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-01011-x · Cited by 3
Microbiome Based Diseases Diagnostics
Yadav, M., & Bhambi, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00012-7 · Cited by 3
Huan, P.-F., Wang, L., He, Z.-Q., & He, J. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s367016 · Cited by 3
“In addition, the decline in the number of Prerevotella may result in decreased mucin synthesis and increased intestinal permeability.(12) In the feces samples of PD”
BackgroundHernández-García, J., Muro-Reche, P., & Orenes‐Piñero, E. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05271-6 · Cited by 5
“…and Bifidobacterium sp. [ 49] and the family Verrucomicrobiaceae, including the genus Akkermansia sp., in PD, whereas others have shown a decrease in the genera Faecalibacterium sp. [ 50], Copro-coccus sp., Blautia sp. [ 49], Prevotella sp. [ 51] and others within the family Prevotellaceae [49].”
STRUCTURAL BASES OF GASTROINTESTINAL MOTILITY CHANGES IN PARKINSON’S DISEASE: STUDY IN RATS
ALBUQUERQUE, J. C. S., Mendes, T. S., Brandão, M. G. S. A., Frota, A. F., Thomas Dominik de Souza dos, R. E. I. S., Aguiar, L. M. V., & da Graça, J. R. V. (2020) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-672020200003e1548 · Cited by 3
Wpływ mikrobioty jelitowej na występowanie zaburzeń psychicznych oraz chorób neurodegeneracyjnych
Frej−Mądrzak, M., Kołodziej, P., Sarowska, J., & Jama−Kmiecik, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2021-0021 · Cited by 3
Metadata
- Authors
- Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Yakult Central Institute (JP)
- Aichi University of Education (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-05
- Volume
- 10
- Issue
- 11
- Pages
- e0142164
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4634857
- OpenAlex
- W2097335121
- Cited by
- 523
- References
- 51
- Citations by year
- 2026: 28 · 2025: 38 · 2024: 51 · 2023: 79 · 2022: 70 · 2021: 80 · 2020: 57 · 2019: 41 · 2018: 51 · 2017: 22 · 2016: 6
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science (15K09350, 25870317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, lipopolysaccharide-binding protein, intestinal permeability, Lactobacillus, Clostridium coccoides, Bacteroides fragilis, hydrogen-producing bacteria, Lactobacillus gasseri, constipation, diamine oxidase, intestinal mucosal integrity, fecal microbiota, disease progression
- MeSH terms
- Lipopolysaccharide-Binding Protein, Acute-Phase Proteins, Aged, Bacteria, Carrier Proteins, Constipation, DNA, Bacterial, Feces, Female, Humans, Intestinal Mucosa, Male, Membrane Glycoproteins, Parkinson Disease, Permeability, RNA, Ribosomal, 16S, Case-Control Studies, Metagenome, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.